IP Library Granted Patent US 9,145,588
Granted Patent B2
US 9,145,588 · App. 13/627,381 · Granted Sep 29, 2015

Generation of binding molecules

Inventors: Mark Throsby (Utrecht, NL); Ton Logtenberg (Utrecht, NL); John De Kruif (Bilthoven, NL)
Assignee: MERUS BIOPHARMACEUTICALS B.V.
C12Q1/6869C07K16/00C07K16/1018C07K16/2863C07K16/32C07K16/468C07K2317/565C40B30/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,145,588
App. No.
13/627,381
Granted
Sep 29, 2015
Kind
B2
Abstract

Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.

Claims (27)

1. A method for producing a population of antibodies which bind to an antigen, said method comprising:

a) providing a population of B cells from one transgenic mouse immunized with said antigen,

wherein said antigen is essentially pure,

wherein said population of B cells comprises essentially all B cells obtained from one or more lymphoid organs of said immunized mouse,

wherein said transgenic mouse expresses a single rearranged human antibody light chain variable region (VL) from a VL nucleic acid,

wherein the single rearranged human VL nucleic acid is a rearranged IgVκ/IGJκ nucleic acid,

wherein the IgVκ nucleic acid is a germline IgVκ gene and the IGJκ nucleic acid is a germline IGJκ gene,

wherein the IgVκ/IGJκ nucleic acid is resistant to DNA rearrangements and somatic hypermutations,

wherein said transgenic mouse expresses a human antibody heavy chain variable region (VH) repertoire from a repertoire of VH nucleic acids,

said B cell population expressing a repertoire of VHs and a single rearranged human VL,

said B cell population expressing a limited immunoglobulin light chain variable (VL) region repertoire,

b) obtaining essentially all of the nucleic acids encoding antibody heavy chain variable (VH) regions from essentially all of said B cells,

c) obtaining nucleotide sequences of essentially all obtained nucleic acids of step b),

d) determining the frequency of nucleotide sequences from step c) which encode VH regions with unique HCDR3 amino acid sequences,

e) selecting nucleic acids encoding VH regions comprising frequently occurring HCDR3 amino acid sequences identified in step d),

f) providing host cells, wherein each host cell comprises at least one vector comprising a nucleotide sequence encoding at least one VH region selected in step e) wherein each said host cell expresses the single rearranged human VL nucleic acid of step a) and at least one VH region selected in step e),

g) culturing said host cells from step f) and allowing for expression of said VL and VH regions, and

h) obtaining said population of antibodies from the cultured host cells of step g) which bind said antigen.

2. A method according to claim 1 , further comprising amplification of nucleic acids encoding antibody heavy chain variable regions from the nucleic acids of step b).

3. A method according to claim 1 , further comprising subjecting a sample of said cultured host cells expressing said VL and VH regions of step g) to at least one functional assay, and selecting at least one cell that expresses an antibody which binds said antigen.

4. A method according to claim 1 , wherein said population of antibodies is of bispecific antibodies.

5. A method according to claim 1 , wherein the germline IgVκ gene is IGκV1*39.

6. A method according to claim 1 , wherein VH regions comprising at least the 20 most abundant HCDR3s are selected.

7. A method according to claim 6 , wherein VH regions comprising the 200 most abundant HCDR3s are selected.

8. A method according to claim 1 , further comprising preparing a mixture of antibodies using the antibodies obtained in step h).

9. A method according to claim 8 , wherein the mixture of antibodies is of bispecific antibodies.

10. A method according to claim 1 , wherein the transgenic mouse has been immunized with a nucleic acid encoding said antigen.

Assignments (5)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Jan 30, 2026
From: MERUS B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 074562/0322 →
SECURITY INTEREST Recorded Jan 29, 2026
From: MERUS B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 074532/0434 →
CHANGE OF ADDRESS Recorded Feb 10, 2017
From: MERUS N.V.
To: MERUS N.V.
Reel/Frame 041676/0807 →
CHANGE OF NAME Recorded Jul 12, 2016
From: MERUS B.V.
To: MERUS N.V.
Reel/Frame 039480/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2012
From: THROSBY, MARK; LOGTENBERG, TON; DE KRUIF, JOHN
To: MERUS BIOPHARMACEUTICALS B.V.
Reel/Frame 029537/0488 →
Continuity (2)
Provisional Application 61539116 · Sep 26, 2011
Related Publication 20130096020A1 · Apr 18, 2013